Pulmonary vascular dysfunction without pulmonary hypertension: A distinct phenotype in idiopathic pulmonary fibrosis.

Authors:
Nathan SD; Tehrani B; Zhao Q; Arias R; Kim D and 10 more

Journal:
Pulm Circ

Publication Year: 2024

DOI:
10.1002/pul2.12311

PMCID:
PMC10762875

PMID:
38174158

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Pulm Circ

Abbreviation: Pulm Circ

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Cardiac & Cardiovascular Systems

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Actigraphy methodology in the Kids Mod PAH trial: Physical activity as a functional endpoint in ped…
Avitabile CM; Krishnan US; Yung D and 16 more (2024) - Transparency Score: 3/6
Clinical evaluation of code-based algorithms to identify patients with pulmonary arterial hypertens…
Didden EM; Lu D; Hsi A and 3 more (2024) - Transparency Score: 3/6
CS1, a controlled-release formulation of valproic acid, for the treatment of patients with pulmonar…
Benza RL; Adamson PB; Bhatt DL and 4 more (2024) - Transparency Score: 3/6
Hemodynamic response to inhaled nitric oxide in patients with pulmonary hypertension and chronic ki…
Del Valle KT; Krowka MJ; Schinstock CA and 6 more (2024) - Transparency Score: 3/6
Patients with CTEPH and mild hemodynamic severity of disease improve to a similar level of exercise…
van Kan C; Tramper J; Bresser P and 8 more (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"CONFLICTS OF INTEREST STATEMENT S. D. N. is a consultant for United Therapeutics, Roche, Bellerophon, and Merck. He is on the speaker bureau for United Therapeutics and Boehringer‐Ingelheim. O. A. S. is a consultant for United Therapeutics, Janssen, and Altavant, and serves on the speaker bureau of United Therapeutics, Bayer, and Janssen. B. R. L. is an employee of Fluidda, Inc. C. S. K. is a consultant for United Therapeutics, Actelion, Altavant, Merck, and Boehringer‐Ingelheim. The remaining authors declare no conflict of interest."

Evidence found in paper:

"The authors have no funding to report."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025